You are here

  • Home
  • Archive
  • Volume 34, Issue Suppl 1
  • 892 Management of patients with hypersensitivity to platinum salts and in gynaecological cancers: a survey from the european network of young gynaecologic oncologists (ENYGO)

Article Text

Article menu
Download PDFPDF
Poster and E-Posters
14. Organization of gynaecological cancer care
892 Management of patients with hypersensitivity to platinum salts and in gynaecological cancers: a survey from the european network of young gynaecologic oncologists (ENYGO)
  1. Tibor A Zwimpfer1,2,
  2. Esra Bilir3,4,
  3. Khayal Gasimli5,
  4. Andrej Cokan6,
  5. Nicolo Bizzarri7,
  6. Zoia Razumova8,
  7. Joanna Kacpercyk-Bartnik9,
  8. Tanja Nikolova10,
  9. Tereza Cicakova11,
  10. Marcus Vetter12,
  11. Celine Montavon2,
  12. Gilberto Morgan13 and
  13. Viola Heinzelmann-Schwarz2
  1. 1Cancer Research, Peter MacCallum Cancer Center, Melbourne, Australia
  2. 2Gynecological Cancer Center, University Hospital Basel, Basel, Switzerland
  3. 3Department of Global Health, Koç University Graduate School of Health Sciences, Istanbul, Turkey
  4. 4Department of Gynecologic Oncology, Koç University School of Medicine, Istanbul, Turkey
  5. 5Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Frankfurt Goethe University Hospital, Frankfurt, Germany
  6. 6Department for gynaecological and breast oncology, University Medical Centre Maribor, Maribor, Slovenia
  7. 7UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
  8. 8Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
  9. 9II Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland
  10. 10Department of Obstetrics and Gynecology, Klinikum Mittelbaden, Academic Teaching Hospital of Heidelberg University, Heidelberg, Germany
  11. 11ESGO Office, Prague, Czech Republic
  12. 12Cancer Center, Cantonal Hospital Baselland, Medical University Clinic, Liestal, Switzerland
  13. 13Skåne University Hospital, Lund, Sweden

Abstract

Introduction/Background Exposure to platinum and taxane-based chemotherapy is associated with the risk of developing hypersensitivity reactions (HSRs), which may necessitate the use of less effective treatments to avoid anaphylaxis. Desensitisation to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen; therefore, this study investigated the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynaecological cancers.

Methodology We conducted a cross-sectional survey among gynaecological and medical oncologist consisting of 33 questions. SurveyMonkey software was used to create and distribute the questionnaire. The survey was posted online on the ENYGO and Oncoalert social media channels and data were collected from 1) members of ENYGO and ESGO and 2)ESGO/ENYGO followers.

Results A total of 144 respondents completed the survey and 133 respondents were included in the final analysis. The gender of the participants was balanced with 54.9% female and 45.1% male with an average age of 38 years. The majority of participants were gynaecological oncologists (43.6%) and medical oncologists (33.8%) working mainly in a university hospital (57.1%) and 77.4%(n=103) were involved in chemotherapy treatment. Of these, 79 participants administered platinum and 67 participants taxane-based chemotherapy. The majority of participants experienced more than 5 HSRs to platinum and taxane per year (73.4% and 73.1%, respectively). Pre-medication with antihistamines/steroids and a new attempt at standard infusion with platinum or taxane chemotherapy were used in 84.8% and 92.5% of Grade 1–2 HSRs to platinum and taxane, respectively. In contrast, tolerance induction was used in 49.4% and 41.8% of Grade 3–4 HSRs to platinum and taxane, respectively. Tolerance induction was mainly performed by medical oncologists,allergists and gynaecological oncologists.

Conclusion The majority of participants strongly emphasised the need to standardise the management of platinum and taxane HSR in gynaecological cancer and to develop international guidelines, regardless of their involvement in chemotherapy treatment.

Disclosures All of the authors have no conflicts of interest to disclose.

https://doi.org/10.1136/ijgc-2024-ESGO.1088

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.